Edoxaban Exposure-Response Analysis and Clinical Utility Index Assessment in Patients With Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism.

about

The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review.Elongated plant virus-based nanoparticles for enhanced delivery of thrombolytic therapies.

P2860

Q39233249-2FA9AEAC-54BE-4987-9F75-C387885EEC3D Q40053619-111C4825-5040-4A7A-865A-753EAA9DC185

P2860

Edoxaban Exposure-Response Analysis and Clinical Utility Index Assessment in Patients With Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism.

Item

http://www.wikidata.org/entity/Q36840816

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Edoxaban Exposure-Response Ana ...... ombosis or Pulmonary Embolism.

@en

type

Item

label

Edoxaban Exposure-Response Ana ...... ombosis or Pulmonary Embolism.

@en

prefLabel

Edoxaban Exposure-Response Ana ...... ombosis or Pulmonary Embolism.

@en

P1476

Edoxaban Exposure-Response Ana ...... rombosis or Pulmonary Embolism

@en

P2093

J Nyberg

http://www.w3.org/2001/XMLSchema#string

K E Karlsson

http://www.w3.org/2001/XMLSchema#string

M O Karlsson

http://www.w3.org/2001/XMLSchema#string

Oqp Yin

http://www.w3.org/2001/XMLSchema#string

R Miller

http://www.w3.org/2001/XMLSchema#string

P2860

Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.

Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programming.

PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles.

Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor.

Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.

Do women bleed more than men when prescribed novel oral anticoagulants for venous thromboembolism? A sex-based meta-analysis.

Population pharmacokinetics of edoxaban in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism--the Hokusai-VTE phase 3 study

Use of anticoagulants in elderly patients.

P304

222-232

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PSP4.12077

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Siv Jönsson

Ulrika S H Simonsson

P577

2016-04-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27299709

http://www.w3.org/2001/XMLSchema#string

P921

thrombosis

P932

4846783

http://www.w3.org/2001/XMLSchema#string

Edoxaban Exposure-Response Analysis and Clinical Utility Index Assessment in Patients With Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism.

about

P2860

P2860

Edoxaban Exposure-Response Analysis and Clinical Utility Index Assessment in Patients With Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932